Programmed Cell Death-1/Programmed Death-ligand 1 Pathway: A New Target for Sepsis
Objective: Sepsis remains a leading cause of death in many Intensive Care Units worldwide. Immunosuppression has been a primary focus of sepsis research as a key pathophysiological mechanism. Given the important role of the negative costimulatory molecules programmed cell death-1 (PD-1) and programm...
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer
2017-01-01
|
Series: | Chinese Medical Journal |
Subjects: | |
Online Access: | http://www.cmj.org/article.asp?issn=0366-6999;year=2017;volume=130;issue=8;spage=986;epage=992;aulast=Liu |
id |
doaj-9d68d6d17f3f4fd3b7ec9959df9b773c |
---|---|
record_format |
Article |
spelling |
doaj-9d68d6d17f3f4fd3b7ec9959df9b773c2020-11-25T00:34:58ZengWolters KluwerChinese Medical Journal0366-69992017-01-01130898699210.4103/0366-6999.204113Programmed Cell Death-1/Programmed Death-ligand 1 Pathway: A New Target for SepsisQiang LiuChun-Sheng LiObjective: Sepsis remains a leading cause of death in many Intensive Care Units worldwide. Immunosuppression has been a primary focus of sepsis research as a key pathophysiological mechanism. Given the important role of the negative costimulatory molecules programmed cell death-1 (PD-1) and programmed death-ligand 1 (PD-L1) in the occurrence of immunosuppression during sepsis, we reviewed literatures related to the PD-1/PD-L1 pathway to examine its potential as a new target for sepsis treatment. Data Sources: Studies of the association between PD-1/PD-L1 and sepsis published up to January 31, 2017, were obtained by searching the PubMed database. Study Selection: English language studies, including those based on animal models, clinical research, and reviews, with data related to PD-1/PD-L1 and sepsis, were evaluated. Results: Immunomodulatory therapeutics could reverse the deactivation of immune cells caused by sepsis and restore immune cell activation and function. Blockade of the PD-1/PD-L1 pathway could reduce the exhaustion of T-cells and enhance the proliferation and activation of T-cells. Conclusions: The anti-PD-1/PD-L1 pathway shows promise as a new target for sepsis treatment. This review provides a basis for clinical trials and future studies aimed at revaluating the efficacy and safety of this targeted approach.http://www.cmj.org/article.asp?issn=0366-6999;year=2017;volume=130;issue=8;spage=986;epage=992;aulast=LiuImmunosuppression; Programmed Cell Death-1; Programmed Death-ligand 1; Sepsis |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Qiang Liu Chun-Sheng Li |
spellingShingle |
Qiang Liu Chun-Sheng Li Programmed Cell Death-1/Programmed Death-ligand 1 Pathway: A New Target for Sepsis Chinese Medical Journal Immunosuppression; Programmed Cell Death-1; Programmed Death-ligand 1; Sepsis |
author_facet |
Qiang Liu Chun-Sheng Li |
author_sort |
Qiang Liu |
title |
Programmed Cell Death-1/Programmed Death-ligand 1 Pathway: A New Target for Sepsis |
title_short |
Programmed Cell Death-1/Programmed Death-ligand 1 Pathway: A New Target for Sepsis |
title_full |
Programmed Cell Death-1/Programmed Death-ligand 1 Pathway: A New Target for Sepsis |
title_fullStr |
Programmed Cell Death-1/Programmed Death-ligand 1 Pathway: A New Target for Sepsis |
title_full_unstemmed |
Programmed Cell Death-1/Programmed Death-ligand 1 Pathway: A New Target for Sepsis |
title_sort |
programmed cell death-1/programmed death-ligand 1 pathway: a new target for sepsis |
publisher |
Wolters Kluwer |
series |
Chinese Medical Journal |
issn |
0366-6999 |
publishDate |
2017-01-01 |
description |
Objective: Sepsis remains a leading cause of death in many Intensive Care Units worldwide. Immunosuppression has been a primary focus of sepsis research as a key pathophysiological mechanism. Given the important role of the negative costimulatory molecules programmed cell death-1 (PD-1) and programmed death-ligand 1 (PD-L1) in the occurrence of immunosuppression during sepsis, we reviewed literatures related to the PD-1/PD-L1 pathway to examine its potential as a new target for sepsis treatment.
Data Sources: Studies of the association between PD-1/PD-L1 and sepsis published up to January 31, 2017, were obtained by searching the PubMed database.
Study Selection: English language studies, including those based on animal models, clinical research, and reviews, with data related to PD-1/PD-L1 and sepsis, were evaluated.
Results: Immunomodulatory therapeutics could reverse the deactivation of immune cells caused by sepsis and restore immune cell activation and function. Blockade of the PD-1/PD-L1 pathway could reduce the exhaustion of T-cells and enhance the proliferation and activation of T-cells.
Conclusions: The anti-PD-1/PD-L1 pathway shows promise as a new target for sepsis treatment. This review provides a basis for clinical trials and future studies aimed at revaluating the efficacy and safety of this targeted approach. |
topic |
Immunosuppression; Programmed Cell Death-1; Programmed Death-ligand 1; Sepsis |
url |
http://www.cmj.org/article.asp?issn=0366-6999;year=2017;volume=130;issue=8;spage=986;epage=992;aulast=Liu |
work_keys_str_mv |
AT qiangliu programmedcelldeath1programmeddeathligand1pathwayanewtargetforsepsis AT chunshengli programmedcelldeath1programmeddeathligand1pathwayanewtargetforsepsis |
_version_ |
1725311210188963840 |